Human immunoglobulin G not checked
CSL Behring · IgPro20 · CSL787
FollowEvery change as it happens, and a Monday email
Trials
2 active
6 in total · 4 in the EU
Targets
—
None known yet
What this is
- How it works
- Human Immunoglobulin G FDA class
- How it’s given
- “CSL787 high or low doses once daily (QD) will be administered via inhalation over a period of 52 weeks.”In the company’s words, NCT07048262 on ClinicalTrials.gov
- Main trialPhase 3
- “This is a prospective, multicenter, open-label, single-arm study to assess the efficacy, safety, and pharmacokinetics (PK) of IgPro20 in adults with hematologic malignancies treated with B-cell targeting Chimeric antigen receptor T-cell (CAR T-cell) and T-cell redirecting therapies (such as T-cell engager bispecific antibody \[TCE BsAb\] therapy). The primary objective is to demonstrate that true annualized rate of serious bacterial infection (SBIs) is less than (\<) 1.0. This study includes two cohorts: 1. Loading Cohort: Participants with serum immunoglobulin G (IgG) \< 500 milligrams per…”In the company’s words, NCT07648264 on ClinicalTrials.gov
- Other names
- IgPro20 · HIZENTRA · CSL787
Other drugs for Secondary Immune Deficiency
- Givinostat HydrochlorideItalfarmaco · Phase 3
- QTX-2101Quetzal Therapeutics · Phase 3
- RusfertideProtagonist Therapeutics, Inc. · Phase 3
- ZiftomenibKura Oncology, Inc. · Phase 3
- PelabresibNovartis · Phase 3
- AG-236Agios Pharmaceuticals, Inc. · Phase 2/3
Coming up2
- 6 May 2029Phase 2 trial completes · ClinicalTrials.gov
- 27 Sep 2029Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials6
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 27 Sep 2029 | Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies | |
| Phase 2Recruiting | 6 May 2029 | Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults With Non-cystic Fibrosis Bronchiectasis (NCFB) | |
| Phase 3Terminated | 2 Dec 2024 | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM) | |
| Phase 3Terminated | 20 Jun 2025 | Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS | |
| Phase 2Completed | 17 May 2022 | Safety and Pharmacokinetics of IgPro20 and IgPro10 in Adults With Systemic Sclerosis (SSc) | |
| Phase 1Completed | 12 Mar 2023 | Study to Assess CSL787 in Non-cystic Fibrosis Bronchiectasis (NCFB) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026